EA023044B1 - Соединения-ингибиторы сигналинга, опосредуемого рецептором notch - Google Patents

Соединения-ингибиторы сигналинга, опосредуемого рецептором notch Download PDF

Info

Publication number
EA023044B1
EA023044B1 EA201490161A EA201490161A EA023044B1 EA 023044 B1 EA023044 B1 EA 023044B1 EA 201490161 A EA201490161 A EA 201490161A EA 201490161 A EA201490161 A EA 201490161A EA 023044 B1 EA023044 B1 EA 023044B1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
mmol
compound
pharmaceutically acceptable
hydrate
Prior art date
Application number
EA201490161A
Other languages
English (en)
Russian (ru)
Other versions
EA201490161A1 (ru
Inventor
Филип Артур Хипскинд
Грегори Алан Стефенсон
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201490161A1 publication Critical patent/EA201490161A1/ru
Publication of EA023044B1 publication Critical patent/EA023044B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
EA201490161A 2011-07-27 2012-07-18 Соединения-ингибиторы сигналинга, опосредуемого рецептором notch EA023044B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161512016P 2011-07-27 2011-07-27
US201161560486P 2011-11-16 2011-11-16
PCT/US2012/047100 WO2013016081A1 (en) 2011-07-27 2012-07-18 Notch pathway signaling inhibitor compound

Publications (2)

Publication Number Publication Date
EA201490161A1 EA201490161A1 (ru) 2014-04-30
EA023044B1 true EA023044B1 (ru) 2016-04-29

Family

ID=46598983

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490161A EA023044B1 (ru) 2011-07-27 2012-07-18 Соединения-ингибиторы сигналинга, опосредуемого рецептором notch

Country Status (36)

Country Link
US (1) US8569286B2 (es)
EP (1) EP2736920B1 (es)
JP (1) JP6027110B2 (es)
KR (1) KR101578309B1 (es)
CN (1) CN103732612B (es)
AP (1) AP4080A (es)
AR (1) AR087107A1 (es)
AU (1) AU2012287251B2 (es)
BR (1) BR112014001600B1 (es)
CA (1) CA2841178C (es)
CL (1) CL2014000175A1 (es)
CO (1) CO6862159A2 (es)
CR (1) CR20140036A (es)
CY (1) CY1116645T1 (es)
DK (1) DK2736920T3 (es)
DO (1) DOP2014000011A (es)
EA (1) EA023044B1 (es)
EC (1) ECSP14013179A (es)
ES (1) ES2544937T3 (es)
GT (1) GT201400012A (es)
HK (1) HK1194086A1 (es)
HR (1) HRP20150771T1 (es)
HU (1) HUE027534T2 (es)
IL (1) IL229988A (es)
JO (1) JO3148B1 (es)
MA (1) MA35611B1 (es)
ME (1) ME02171B (es)
MX (1) MX356536B (es)
MY (1) MY184303A (es)
PE (1) PE20141061A1 (es)
PL (1) PL2736920T3 (es)
PT (1) PT2736920E (es)
RS (1) RS54135B1 (es)
SI (1) SI2736920T1 (es)
TW (1) TWI568730B (es)
WO (1) WO2013016081A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110506A2 (en) * 2013-01-14 2014-07-17 The Trustees Of Columbia University In The City Of New York Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk抑制劑
TWI609687B (zh) * 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
TWI625332B (zh) * 2015-07-07 2018-06-01 美國禮來大藥廠 刻痕(notch)路徑傳訊抑制化合物
EA201891620A1 (ru) 2016-02-05 2019-02-28 Денали Терапьютикс Инк. Ингибиторы взаимодействующей с рецептором протеинкиназы 1
EP3429571A1 (en) 2016-03-15 2019-01-23 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for use in the treatment of solid tumors
EP3442529B1 (en) * 2016-04-12 2021-05-26 Eli Lilly and Company Combination therapy with notch and cdk4/6 inhibitors for the treatment of lung cancer
AU2017249988C1 (en) * 2016-04-12 2023-02-16 Eli Lilly And Company Combination therapy with notch and PI3K/mTOR inhibitors for use in treating cancer
CN109475629A (zh) * 2016-05-20 2019-03-15 伊莱利利公司 用notch和pd-1或pd-l1抑制剂的组合治疗
JP2019526632A (ja) 2016-08-31 2019-09-19 イーライ リリー アンド カンパニー 固形腫瘍の治療のための投薬レジメン
CA3039405A1 (en) 2016-10-12 2018-04-19 Eli Lilly And Company Targeted treatment of mature t-cell lymphoma
HRP20220636T1 (hr) 2016-12-09 2022-07-22 Denali Therapeutics Inc. Spojevi korisni kao inhibitori ripk1
US11845803B2 (en) 2017-02-17 2023-12-19 Fred Hutchinson Cancer Center Combination therapies for treatment of BCMA-related cancers and autoimmune disorders
BR112020008638A2 (pt) 2017-11-01 2020-10-20 Juno Therapeutics Inc receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma)
WO2019090364A1 (en) * 2017-11-06 2019-05-09 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
EP3790552A4 (en) * 2018-05-06 2022-06-15 Ayala Pharmaceuticals Inc. COMBINATION COMPOSITIONS WITH BISFLUORAKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND METHODS OF USE THERE
CA3114113A1 (en) 2018-10-02 2020-04-09 Frequency Therapeutics, Inc. Pharmaceutical compositions and methods related to otic therapeutic agents
BR112021020141A2 (pt) 2019-04-08 2021-12-21 Frequency Therapeutics Inc Combinação de chir99021 e ácido valpróico para tratamento de perda auditiva

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028268A2 (en) * 1996-12-23 1998-07-02 Elan Pharmaceuticals, Inc. CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS
WO2011060051A1 (en) * 2009-11-12 2011-05-19 University Of Massachusetts Methods for treating glioblastoma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518483A (ja) * 1998-06-22 2002-06-25 エラン ファーマシューティカルズ,インコーポレイテッド β−アミロイドペプチド放出を阻害するための化合物および/またはその合成
AU4707999A (en) 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
WO2004069826A1 (en) 2003-02-04 2004-08-19 F. Hoffmann-La Roche Ag Malonamide derivatives as gamma-secretase inhibitors
ATE428698T1 (de) 2003-09-09 2009-05-15 Hoffmann La Roche Die aktivität von gamma-secretase blockierende malonamidderivate
KR100884872B1 (ko) 2003-10-06 2009-02-23 에프. 호프만-라 로슈 아게 감마-세크레타제 저해제로서 유용한 치환된다이벤조-아제핀 및 벤조-다이아제핀 유도체
CN101410378B (zh) 2006-03-27 2012-12-05 霍夫曼-拉罗奇有限公司 作为γ分泌酶抑制剂的丙二酰胺衍生物
CN101622232A (zh) * 2007-02-02 2010-01-06 弗·哈夫曼-拉罗切有限公司 6-氧代-6,7-二氢-5h-二苯并[b,d]氮杂䓬-7-基衍生物
BRPI0906831A2 (pt) 2008-01-11 2019-09-24 Hoffmann La Roche uso de um inibidor de gama-secretase para tratamento de câncer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028268A2 (en) * 1996-12-23 1998-07-02 Elan Pharmaceuticals, Inc. CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS
WO2011060051A1 (en) * 2009-11-12 2011-05-19 University Of Massachusetts Methods for treating glioblastoma

Also Published As

Publication number Publication date
AR087107A1 (es) 2014-02-12
JP6027110B2 (ja) 2016-11-16
MY184303A (en) 2021-03-31
HUE027534T2 (en) 2016-11-28
AU2012287251A1 (en) 2014-01-30
DOP2014000011A (es) 2014-07-31
CN103732612B (zh) 2015-09-23
JP2014527042A (ja) 2014-10-09
DK2736920T3 (en) 2015-07-20
ECSP14013179A (es) 2014-03-31
TW201315732A (zh) 2013-04-16
KR20140026624A (ko) 2014-03-05
GT201400012A (es) 2014-07-16
EP2736920B1 (en) 2015-07-01
CO6862159A2 (es) 2014-02-10
TWI568730B (zh) 2017-02-01
AU2012287251B2 (en) 2015-05-14
CR20140036A (es) 2014-03-21
HK1194086A1 (en) 2014-10-10
ME02171B (me) 2015-10-20
US20130029972A1 (en) 2013-01-31
WO2013016081A1 (en) 2013-01-31
US8569286B2 (en) 2013-10-29
MA35611B1 (fr) 2014-11-01
HRP20150771T1 (hr) 2015-08-28
AP2014007362A0 (en) 2014-01-31
AP4080A (en) 2017-03-29
PE20141061A1 (es) 2014-09-06
PT2736920E (pt) 2015-09-16
NZ618891A (en) 2015-12-24
PL2736920T3 (pl) 2015-11-30
CL2014000175A1 (es) 2014-08-22
CN103732612A (zh) 2014-04-16
CY1116645T1 (el) 2017-03-15
SI2736920T1 (sl) 2015-08-31
IL229988A (en) 2017-07-31
ES2544937T3 (es) 2015-09-07
CA2841178A1 (en) 2013-01-31
KR101578309B1 (ko) 2015-12-16
RS54135B1 (en) 2015-12-31
BR112014001600B1 (pt) 2022-09-13
MX356536B (es) 2018-06-01
JO3148B1 (ar) 2017-09-20
MX2014001084A (es) 2014-02-27
EA201490161A1 (ru) 2014-04-30
CA2841178C (en) 2016-12-20
BR112014001600A2 (pt) 2017-02-21
EP2736920A1 (en) 2014-06-04

Similar Documents

Publication Publication Date Title
EA023044B1 (ru) Соединения-ингибиторы сигналинга, опосредуемого рецептором notch
US20230226035A1 (en) Small molecules against cereblon to enhance effector t cell function
JP7462985B2 (ja) 芳香族化合物および抗腫瘍薬物の調製におけるその使用
CA3110502C (en) Pyrazolo[3,4-b]pyridine compounds as inhibitors of tam and met kinases
CN104870442B (zh) 双环杂环化合物及其治疗用途
CN104870440B (zh) 双环杂环化合物及其治疗用途
MX2015002887A (es) Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello.
JP6412278B2 (ja) 平滑筋肉腫の標的治療
EP3341379B1 (en) Inhibitors of ezh2
EA005996B1 (ru) Пирролзамещенный 2-индолинон, фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой
EA028035B1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
CN109336883A (zh) 双环杂环化合物及其治疗用途
EA027563B1 (ru) Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
EP3027602B1 (fr) Nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN113301963A (zh) 用于治疗癌症的作为nlrp3调节剂的取代的喹唑啉类
KR20050113612A (ko) 인돌리논 화합물을 사용한 과도한 골 용해의 치료
KR20210135521A (ko) 피롤로피라졸 유도체
CA3068146A1 (en) Heterochromatin gene repression inhibitors
WO2018145217A1 (en) Human ets-related gene (erg) compounds as therapeutics and methods for their use
WO2008070161A1 (en) Azepans and methods for making and using same
JPWO2021168313A5 (es)
ZA200506371B (en) Treatment of excessive osteolysis with indolinone compounds
NZ618891B2 (en) Notch pathway signaling inhibitor compound
TW202400608A (zh) 雜芳族巨環醚化合物之固體形式、醫藥組合物及製備
WO2023215449A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KG TJ TM